Mukka Proteins Limited — Others, 14-11-2024: Statement of deviation(s) or variation(s) under Reg. 32

Mukka Proteins Limited has announced a board meeting to review the statement of deviation in the utilization of funds raised through its IPO for the quarter ended 30th September 2024. The company confirmed there was no deviation in fund usage from the objectives outlined in the prospectus dated March 5, 2023. A total of ₹224 crore was raised, allocated primarily for working capital and investment in an associate. The Audit Committee and auditors found no discrepancies. This consistent funding approach could instill investor confidence and suggest a positive outlook on the company’s operational stability.